TUESDAY, July 31, 2018 (HealthDay News) -- Azedra (iobenguane) has been approved by the U.S. Food and Drug Administration to treat people 12 and older with rare adrenal gland tumors that can't be surgically removed and have spread beyond the original site.
Latest Cancer News
The adrenal glands sit above the kidneys and produce the stress hormones epinephrine and norepinephrine. The rare tumors known as pheochromocytomas spike production of these hormones, leading to possible symptoms including high blood pressure, headache, irritability, excessive sweating and rapid heartbeat. Sometimes, such tumors develop outside the adrenal gland, where they're called paragangliomas, the FDA said in a news release.
"Many patients with these ultra-rare cancers can be treated with surgery or local therapies, but there are no effective systemic treatments for patients who experience tumor-related symptoms such as high blood pressure," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.
The drug's label includes a warning that users should minimize exposure to radiation; the warning applies especially to younger patients, the FDA said. Among a number of additional warnings, pregnant women shouldn't take Azedra since it can harm a fetus.
Azedra is produced by Progenics Pharmaceuticals, based in Tarrytown, N.Y.
-- Scott Roberts
Copyright © 2018 HealthDay. All rights reserved.